CAMBRIDGE, Mass., May 18, 2016 (GLOBE NEWSWIRE) -- Metabolix, Inc. (NASDAQ:MBLX) announced today that it has entered into an amendment to its license agreement with Tepha, Inc., a Lexington, Massachusetts based medical device company that licenses Metabolix PHA biopolymer technology for use in certain medical applications. The amendment calls for a $2.0 million lump sum payment to Metabolix. In exchange, Metabolix agreed to forgo future royalties under its existing license agreement with Tepha and to provide two additional Metabolix production strains and related intellectual property to Tepha for use in the production of Tepha's medical devices.

As previously announced, Metabolix is evaluating strategic alternatives for its specialty biopolymers business and Yield10 crop science program and is engaged in ongoing efforts to secure additional funding for its strategic review process and operations.
​
Read More: http://ir.metabolix.com/releasedetail.cfm?ReleaseID=971552

NEW YORK, New York, May 5, 2016 — Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that the Company has launched a new website, CiraraStories.com, which will feature people afflicted by this devastating condition – patients, their families, and the medical professionals who care for them.

The video stories are sponsored by Remedy Pharmaceuticals, makers of CIRARA™, a drug designed to prevent edema formation. 

The inaugural video profiles a remarkable woman, Jaclyn who, at age 32, had a large hemispheric infarction (LHI). The LHI occurred the night before her middle child was to start school for the first time. She had just set out his lunch box, went upstairs, and as she lay down on the bed, a strange sensation came over her. Jaclyn tried getting out of bed, but fell, hitting her head on the nightstand, which woke her husband, Jim. Startled, he jumped out of bed and saw his wife lying on the floor, her head bloodied. Jaclyn was paralyzed on her right side and unable to speak. She could only blink her eyes. Jim called 911. We learn what happened when Jaclyn’s family discovered her chances of surviving were poor, the difficult decision they had to make, and how she is doing now.

“Jaclyn’s story reminds us of the important mission we are on to help CNS-related edema victims to not only survive, but live life to the fullest,” notes David Geliebter, Executive Chairman of Remedy Pharmaceuticals.

Read More: http://www.remedypharmaceuticals.com/press-releases/remedy-pharmaceuticals-new-website-spotlights-victims-of-cns-related-edema